USPTO serial 79277955
LIZTOX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 22, 2020
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LIZTOX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Food for babies; lactose for pharmaceutical purposes; nutritional supplements; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical products for the treatment of viral diseases; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals being medicines for alleviating constipation; pharmaceutical products for the treatment of bone diseases; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations, namely, ophthalmic preparations; pharmaceutical preparations for treating allergies; pharmaceutical products for the treatment of cancer; pharmaceutical agents for epidermis; pharmaceuticals being medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating asthma; pharmaceuticals being medicines for dental purposes; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for respiratory organs; pharmaceuticals being antihistamines; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for treating obesity; pharmaceuticals being cardiotonics; cardiovascular pharmaceuticals; pharmaceutical preparations, namely, antipyretic preparations; pharmaceutical preparations, namely, analgesic preparations; pharmaceutical preparations, namely, anti-inflammatory preparations; pharmaceuticals being anaesthetics; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals being chemotherapeutics; pharmaceuticals being psychotropics; pharmaceutical products for skin care for animals; pharmaceutical preparations for the treatment of worms in pets; Veterinary preparations, namely, anti-infective products for veterinary use; Veterinary preparations, namely, veterinary vaccines; veterinary preparations for treatment of intestinal bacteria; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; nutraceutical preparations for therapeutic or medical purposes for the treatment of obesity; nutraceutical preparations for therapeutic or medical purposes for the treatment of intestinal disorders; nutraceutical preparations for therapeutic or medical purposes for the treatment of allergies; nutraceutical preparations for therapeutic or medical purposes for the treatment of gastrointestinal diseases; medicated plasters; deodorants, other than for human beings or for animals, namely, air deodorants, deodorants for clothing, deodorants for textiles, household deodorants, and room deodorants; bacterial preparations for medical and veterinary use; medicine cases, portable, filled, with pharmaceutical preparations for the treatment of viral diseases; medicine cases, portable, filled, with pharmaceutical preparations for the treatment of intestinal disorders; medicine cases, portable, filled, with pharmaceutical preparations for the treatment of inflammatory diseases; sanitary pads; adhesives for dentures; diapers for incontinence; babies' diapers; diapers for pets; fly glue; mothproofing paper | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Huons Global Co., Ltd.
- Other trademarks owned by Huons Global Co., Ltd.
- Other trademarks owned by Huons Bio Pharma Co., Ltd.
- Other trademarks owned by Huons Global Co., Ltd.
- Other trademarks in Class 005
- Similar marks named LIZTOX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 22, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 28, 2021 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jan 30, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 8, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 8, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 22, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 22, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 17, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 2, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 14, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 14, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 14, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 1, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 9, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 9, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 25, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 24, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 19, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 11, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 10, 2020 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Feb 6, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |